{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:21:49Z","timestamp":1762521709245},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1472-6963-14-429","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T05:01:20Z","timestamp":1411534880000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Sandhya","family":"Sapra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Broder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,24]]},"reference":[{"issue":"Suppl 1","key":"3518_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy D: The global burden of hepatitis C. Liver Int. 2009, 29 (Suppl 1): 74-81.","journal-title":"Liver Int"},{"key":"3518_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.20659","volume":"41","author":"BM Spiegel","year":"2005","unstructured":"Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005, 41: 790-800.","journal-title":"Hepatology"},{"key":"3518_CR3","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMp1202608","volume":"366","author":"PJ Clark","year":"2012","unstructured":"Clark PJ, Muir AJ: Overcoming barriers to care for hepatitis C. N Engl J Med. 2012, 366: 2436-2438.","journal-title":"N Engl J Med"},{"key":"3518_CR4","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/hep.23220","volume":"50","author":"ML Volk","year":"2009","unstructured":"Volk ML, Tocco R, Saini S, Lok AS: Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009, 50: 1750-1755.","journal-title":"Hepatology"},{"key":"3518_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006, 144: 705-714.","journal-title":"Ann Intern Med"},{"key":"3518_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL, H\u00e4ussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982.","journal-title":"N Engl J Med"},{"key":"3518_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965.","journal-title":"Lancet"},{"key":"3518_CR8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"MG Swain","year":"2010","unstructured":"Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pess\u00f4a MG, Lin A, Tietz A, Connell EV, Diago M: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010, 139: 1593-1601.","journal-title":"Gastroenterology"},{"key":"3518_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007, 147: 677-684.","journal-title":"Ann Intern Med"},{"key":"3518_CR10","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1002\/hep.1840360730","volume":"36","author":"MW Fried","year":"2002","unstructured":"Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology. 2002, 36: S237-S244.","journal-title":"Hepatology"},{"key":"3518_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002, 123: 1061-1069.","journal-title":"Gastroenterology"},{"key":"3518_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/ng.453","volume":"41","author":"TR O\u2019Brien","year":"2009","unstructured":"O\u2019Brien TR: Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet. 2009, 41: 1048-1050.","journal-title":"Nat Genet"},{"key":"3518_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364: 1195-1206.","journal-title":"N Engl J Med"},{"key":"3518_CR14","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011, 364: 2405-2416.","journal-title":"N Engl J Med"},{"key":"3518_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.cgh.2010.07.012","volume":"8","author":"LA Beste","year":"2010","unstructured":"Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA: Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol. 2010, 8: 972-978.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3518_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1478-3231.2009.02156.x","volume":"30","author":"AA Butt","year":"2010","unstructured":"Butt AA, McGinnis KA, Skanderson M, Justice AC: Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010, 30: 240-250.","journal-title":"Liver Int"},{"key":"3518_CR17","volume-title":"PriceRx Pro [electronic database]. Wolters Kluwer Health","author":"Average Wholesale Price","year":"2013","unstructured":"Average Wholesale Price: PriceRx Pro [electronic database]. Wolters Kluwer Health. 2013, https:\/\/pricerx.medispan.com. Accessed 9\/27\/2013"},{"key":"3518_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.290.2.228","volume":"290","author":"JA Salomon","year":"2003","unstructured":"Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003, 290: 228-237.","journal-title":"JAMA"},{"key":"3518_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1524-4733.2009.00691.x","volume":"13","author":"D Mitra","year":"2010","unstructured":"Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V: Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010, 13: 479-486.","journal-title":"Value Health"},{"key":"3518_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/ncpgasthep1274","volume":"5","author":"S Zeuzem","year":"2008","unstructured":"Zeuzem S: Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol. 2008, 5: 610-622.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"3518_CR21","unstructured":"PegIntron (peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use [package insert]. 2011, Whitehouse Station, NJ: Merck & Co., Inc"},{"key":"3518_CR22","unstructured":"PEGASYS (peginterferon alfa-2a) Injection for Subcutaneous Use [package insert]. Package Insert. 2011, South San Francisco, CA: Genentech, Inc"},{"key":"3518_CR23","unstructured":"COPEGUS\u00ae (ribavirin) tablets [package insert]. 2011, South San Francisco, CA: Genentech, Inc"},{"key":"3518_CR24","unstructured":"Ribasphere\u00ae (ribavirin, USP) tablets [package insert]. 2012, New York, NY: Kadmon Pharmaceuticals"},{"key":"3518_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1377\/hlthaff.20.6.267","volume":"20","author":"W Hwang","year":"2001","unstructured":"Hwang W, Weller W, Ireys H, Anderson G: Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001, 20: 267-278.","journal-title":"Health Aff (Millwood)"},{"key":"3518_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/JOM.0b013e318162f615","volume":"50","author":"F Papatheofanis","year":"2008","unstructured":"Papatheofanis F, Bookhart BK, Muser E, Piech CT: An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. J Occup Environ Med. 2008, 50: 584-589.","journal-title":"J Occup Environ Med"},{"key":"3518_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1524-4733.2007.00215.x","volume":"11","author":"M Kimel","year":"2008","unstructured":"Kimel M, Leidy NK, Mannix S, Dixon J: Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV\/AIDS, and chronic kidney disease. Value Health. 2008, 11: 57-75.","journal-title":"Value Health"},{"key":"3518_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1176\/appi.ajp.157.8.1274","volume":"157","author":"BG Druss","year":"2000","unstructured":"Druss BG, Rosenheck RA, Sledge WH: Health and disability costs of depressive illness in a major U.S. corporation. Am J Psychiatry. 2000, 157: 1274-1278.","journal-title":"Am J Psychiatry"},{"key":"3518_CR29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/sleep\/30.3.263","volume":"30","author":"RJ Ozminkowski","year":"2007","unstructured":"Ozminkowski RJ, Wang S, Walsh JK: The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007, 30: 263-273.","journal-title":"Sleep"},{"key":"3518_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2710.2008.00912.x","volume":"33","author":"SU Iqbal","year":"2008","unstructured":"Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L: Persistence with hepatitis C therapy in the Department of Veterans Affairs. J Clin Pharm Ther. 2008, 33: 251-261.","journal-title":"J Clin Pharm Ther"},{"key":"3518_CR31","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-125-8-199610150-00002","volume":"125","author":"NN Zein","year":"1996","unstructured":"Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH: Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996, 125: 634-639.","journal-title":"Ann Intern Med"},{"key":"3518_CR32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/aje\/153.8.764","volume":"153","author":"KC Hyams","year":"2001","unstructured":"Hyams KC, Riddle J, Rubertone M, Trump D, Alter MJ, Cruess DF, Han X, Nainam OV, Seeff LB, Mazzuchi JF, Bailey S: Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Am J Epidemiol. 2001, 153: 764-770.","journal-title":"Am J Epidemiol"},{"key":"3518_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"DB Strader","year":"2004","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004, 39: 1147-1171.","journal-title":"Hepatology"},{"key":"3518_CR34","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S: Telaprevir for retreatment of HCV infection. N Engl J Med. 2011, 364: 2417-2428.","journal-title":"N Engl J Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-14-429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-14-429\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-14-429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-14-429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:51:31Z","timestamp":1630565491000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-14-429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3518"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-14-429","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,24]]},"assertion":[{"value":"14 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"429"}}